etidronate has been researched along with Vascular Diseases in 9 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report a beneficial effect of high-dose etidronate, one of the bisphosphonates, on periarticular calcinosis in a case of arterial and periarticular BCP crystal deposition disease." | 7.72 | [Beneficial effect of high-dose etidronate on periarticular calcinosis associated with arterial and periarticular basic calcium phosphate (BCP) crystal deposition disease]. ( Ide, M; Ito, G; Ozaki, S; Suzuki, Y; Uehara, R, 2003) |
| " We report a beneficial effect of high-dose etidronate, one of the bisphosphonates, on periarticular calcinosis in a case of arterial and periarticular BCP crystal deposition disease." | 3.72 | [Beneficial effect of high-dose etidronate on periarticular calcinosis associated with arterial and periarticular basic calcium phosphate (BCP) crystal deposition disease]. ( Ide, M; Ito, G; Ozaki, S; Suzuki, Y; Uehara, R, 2003) |
| "The amount of bone loss in algodystrophy in a few weeks or months is what might be expected over 10 years during the natural history of uncomplicated osteoporosis." | 2.40 | Further vascular, bone and autonomic investigations in algodystrophy. ( Audran, M; Baslé, MF; Bregeon, C; Legrand, E; Masson, C; Namour, A; Pascaretti, C; Renier, JC; Saumet, JL, 1998) |
| "Whereas the articular complications of heterotopic ossification have been well documented, the vascular complications are less well known." | 1.29 | [Heterotopic ossification and vascular compression]. ( Brissot, R; Gallien, P; Le Bot, MP; Nicolas, B; Rivier, I; Robineau, S; Sarkis, S, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Stumpf, MJ | 1 |
| Schaefer, CA | 1 |
| Schahab, N | 1 |
| Okada, Y | 1 |
| Mori, H | 1 |
| Tanaka, Y | 1 |
| Hashimoto, O | 1 |
| Mackenzie, NC | 1 |
| Zhu, D | 1 |
| Longley, L | 1 |
| Patterson, CS | 1 |
| Kommareddy, S | 1 |
| MacRae, VE | 1 |
| Ito, G | 1 |
| Suzuki, Y | 1 |
| Uehara, R | 1 |
| Ide, M | 1 |
| Ozaki, S | 1 |
| Gallien, P | 1 |
| Nicolas, B | 1 |
| Le Bot, MP | 1 |
| Robineau, S | 1 |
| Rivier, I | 1 |
| Sarkis, S | 1 |
| Brissot, R | 1 |
| Masson, C | 1 |
| Audran, M | 1 |
| Pascaretti, C | 1 |
| Namour, A | 1 |
| Saumet, JL | 1 |
| Baslé, MF | 1 |
| Legrand, E | 1 |
| Bregeon, C | 1 |
| Renier, JC | 1 |
| Mori, K | 1 |
| Shioi, A | 1 |
| Jono, S | 1 |
| Nishizawa, Y | 1 |
| Morii, H | 1 |
| Stuart, G | 1 |
| Wren, C | 1 |
| Bain, H | 1 |
| Raper, RF | 1 |
| Ibels, LS | 1 |
2 reviews available for etidronate and Vascular Diseases
| Article | Year |
|---|---|
[Positioning of bisphosphonates for vascular calcification].
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcinosis; Clinical Trial | 2010 |
Further vascular, bone and autonomic investigations in algodystrophy.
Topics: Absorptiometry, Photon; Autonomic Nervous System; Autonomic Nervous System Diseases; Blood Vessels; | 1998 |
7 other studies available for etidronate and Vascular Diseases
| Article | Year |
|---|---|
From osteoporosis to pseudoxanthoma elasticum - etidronate in a vascular disease.
Topics: Etidronic Acid; Humans; Osteoporosis; Pseudoxanthoma Elasticum; Vascular Calcification; Vascular Dis | 2020 |
MOVAS-1 cell line: a new in vitro model of vascular calcification.
Topics: Alkaline Phosphatase; Animals; Anthraquinones; Bone Density Conservation Agents; Calcinosis; Calcium | 2011 |
[Beneficial effect of high-dose etidronate on periarticular calcinosis associated with arterial and periarticular basic calcium phosphate (BCP) crystal deposition disease].
Topics: Calcinosis; Calcium Phosphates; Crystallization; Etidronic Acid; Female; Humans; Joint Diseases; Mid | 2003 |
[Heterotopic ossification and vascular compression].
Topics: Adult; Craniocerebral Trauma; Etidronic Acid; Femoral Vein; Humans; Indomethacin; Male; Middle Aged; | 1994 |
Expression of matrix Gla protein (MGP) in an in vitro model of vascular calcification.
Topics: Alendronate; Animals; Blotting, Northern; Calcinosis; Calcium; Calcium-Binding Proteins; Cattle; Cel | 1998 |
Idiopathic infantile arterial calcification in two siblings: failure of treatment with diphosphonate.
Topics: Calcinosis; Consanguinity; Echocardiography; Etidronic Acid; Female; Fetal Diseases; Humans; Infant, | 1990 |
Osteosclerotic myeloma complicated by diffuse arteritis, vascular calcification and extensive cutaneous necrosis.
Topics: Adult; Aluminum Hydroxide; Arteritis; Bone Neoplasms; Calcinosis; Cyclophosphamide; Etidronic Acid; | 1985 |